Minerva enters $75M ATM offering; Phase 3 roluperidone relapse phase extended to 52 weeks

Minerva Neurosciences, Inc.

Up to $75M in common stock may be sold at-the-market through Leerink Partners; 3% commission.
Phase 3 C19 trial relapse assessment phase extended from 40 to 52 weeks after FDA feedback.
Topline efficacy results from C19 trial expected H2 2027; relapse data expected H2 2028.
No obligation to sell any shares; program provides capital-raising flexibility.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Minerva Neurosciences, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $75.0 million (effective 2026-05-27).

Action: entry
Agreement: atm program
Counterparty: Leerink Partners LLC
Value: up to $75.0 million
Effective: 2026-05-27

Exact text from the filing

On May 27, 2026, Minerva Neurosciences, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Agent”) with respect to an “at-the market” offering program, pursuant to which the Company may issue and sell, from time to time, shares of its common stock, par value $0.0001 per share (“Common Stock”).

View on SEC.gov

Browse all material agreements →

Minerva Neurosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-241930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.